Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis

Trends in Parasitology

Volumn 26, Issue 7, 2010, Pages 341-349

  Reis, Alexandre B ^a,b   Giunchetti, Rodolfo C ^a,b   Carrillo, Eugenia ^c   Martins Filho, Olindo A ^b   Moreno, Javier ^c  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LEISHMANIA VACCINE; PROTOZOAL VACCINE;

CANINE LEISHMANIASIS; CELLULAR IMMUNITY; DOG; HUMORAL IMMUNITY; IMMUNOPROPHYLAXIS; INFECTION CONTROL; INNATE IMMUNITY; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PARASITE IMMUNITY; PARASITE TRANSMISSION; REVIEW; RISK ASSESSMENT; VACCINE PRODUCTION; ANIMAL; DOG DISEASES; IMMUNOLOGY; LEISHMANIASIS, VISCERAL; PARASITOLOGY; VETERINARY;

ANIMALS; DOG DISEASES; DOGS; LEISHMANIA; LEISHMANIASIS, VISCERAL; PROTOZOAN VACCINES;

CANIS FAMILIARIS; LEISHMANIA DONOVANI CHAGASI; LEISHMANIA INFANTUM;

EID: 77953960733     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.04.005     Document Type: Review

References (77)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 2004, 27:305-318.
2. Dujardin J.C. Risk factors in the spread of leishmaniases: towards integrated monitoring?. Trends Parasitol. 2006, 22:4-6.
3. Maia-Elkhoury A.N., et al. Visceral leishmaniasis in Brazil: trends and challenges. Cad. Saude Publica 2008, 24:2941-2947.
4. Maroli M., et al. The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop. Med. Int. Health 2008, 13:256-264.
5. Shaw S.E., et al. Canine leishmaniosis in the United Kingdom: a zoonotic disease waiting for a vector?. Vet. Parasitol. 2009, 163:281-285.
6. Duprey Z.H., et al. Canine Visceral Leishmaniasis, United States and Canada, 2000-2003. Emerg. Infect. Dis. 2006, 12:440-446.
7. Antoniou M., et al. Leishmania donovani leishmaniasis in Cyprus. Lancet Infect. Dis. 2009, 9:76-77.
8. Alvar J., et al. Canine leishmaniasis. Adv. Parasitol. 2004, 57:1-88.
9. Baneth G., Shaw S.E. Chemotherapy of canine leishmaniosis. Vet. Parasitol. 2002, 106:315-324.
10. Quinnell R.J., Courtenay O. Transmission, reservoir host and control of zoonotic visceral leishmaniasis. Parasitology 2009, 136:1915-1934.
11. Gramiccia M., Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. Int. J. Parasitol. 2005, 35:1169-1180.
12. Moreno J., Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol. 2002, 18:399-405.
13. Reis A.B., et al. Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Res. Vet. Sci. 2006, 81:68-75.
14. Reis A.B., et al. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet. Immunol. Immunopathol. 2006, 112:102-116.
15. Reis A.B., et al. Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi. Clin. Exp. Immunol. 2006, 146:303-311.
16. Giunchetti R.C., et al. Relationship between canine visceral leishmaniosis and the Leishmania (Leishmania) chagasi burden in dermal inflammatory foci. J. Comp. Pathol. 2006, 135:100-107.
17. Giunchetti R.C., et al. Histopathological and immunohistochemical investigations of the hepatic compartment associated with parasitism and serum biochemical changes in canine visceral leishmaniasis. Res. Vet. Sci. 2008, 84:269-277.
18. Giunchetti R.C., et al. Histopathology, parasite density and cell phenotypes of the popliteal lymph node in canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 2008, 121:23-33.
19. Guerra L.L., et al. Evaluation of the influence of tissue parasite density on hematological and phenotypic cellular parameters of circulating leukocytes and splenocytes during ongoing canine visceral leishmaniasis. Parasitol. Res. 2009, 104:611-622.
20. Reis A.B., et al. Systemic and compartmentalized immune response in canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 2009, 128:87-95.
21. Menezes-Souza, D. et al. Cytokine and transcription factor profiles in the skin of dogs naturally infected by Leishmania (Leishmania) chagasi and presenting distinct skin parasite density and clinical status. Vet. Parasitol. (in press).
22. Alves C.F., et al. Expression of IFN-gamma, TNF-alpha, IL-10 and TGF-beta in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with Leishmania (Leishmania) chagasi. Vet. Immunol. Immunopathol. 2009, 128:349-358.
23. Alexandre-Pires G., et al. Leishmaniosis - a report about the microvascular and cellular architecture of the infected spleen in Canis familiaris. Microsc. Res. Tech. 2006, 69:227-235.
24. Lage R.S., et al. Analysis of the cytokine profile in spleen cells from dogs naturally infected by Leishmania chagasi. Vet. Immunol. Immunopathol. 2007, 115:135-145.
25. Guarga J.L., et al. Canine leishmaniasis transmission: higher infectivity amongst naturally infected dogs to sand flies is associated with lower proportions of T helper cells. Res. Vet. Sci. 2000, 69:249-253.
26. Chamizo C., et al. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet. Immunol. Immunopathol. 2005, 103:67-75.
27. Manna L., et al. Leishmania DNA load and cytokine expression levels in asymptomatic naturally infected dogs. Vet. Parasitol. 2006, 142:271-280.
28. Carrillo E., et al. Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. Vaccine 2007, 25:1534-1543.
29. Miró G., et al. Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part two. Trends Parasitol. 2008, 24:371-377.
30. Monjour L., et al. Vaccination and treatment trials against murine leishmaniasis with semi-purified Leishmania antigens. Trans. R. Soc. Trop. Med. Hyg. 1988, 82:412-415.
31. Dunan S., et al. Vaccination trial against canine visceral leishmaniasis. Phocean Veterinary Study Group on Visceral Leishmaniasis. Parasite Immunol. 1989, 11:397-402.
32. Skeiky Y.A., et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 1998, 161:6171-6179.
33. Webb J.R., et al. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 1996, 157:5034-5041.
34. Campos-Neto A., et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 2001, 69:4103-4108.
35. Skeiky Y.A., et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002, 20:3292-3303.
36. Coler R.N., et al. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 2007, 75:4648-4654.
37. Gradoni L., et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 2005, 23:5245-5251.
38. Moreno J., et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 2007, 25:5290-5300.
39. Paraguai de Souza E., et al. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 2001, 19:3104-3115.
40. Ghosh A., et al. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001, 20:59-68.
41. Tonui W.K., et al. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect. Immun. 2004, 72:5654-5661.
42. Giunchetti R.C., et al. Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. Vaccine 2007, 25:7674-7686.
43. Mohebali M., et al. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I. R. Iran. Vaccine 2004, 22:4097-4100.
44. Soussi N., et al. Effect of intragastric and intraperitoneal immunisation with attenuated and wild-type LACK-expressing Listeria monocytogenes on control of murine Leishmania major infection. Vaccine 2002, 20:2702-2712.
45. Melby P.C., et al. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 2001, 69:4719-4725.
46. Fujiwara R.T., et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet. Res. 2005, 36:827-838.
47. Ahmed S.B., et al. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 2004, 22:1631-1639.
48. Aguilar-Be I., et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect. Immun. 2005, 73:812-819.
49. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008, 26:1709-1724.
50. Santos W.R., et al. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 2002, 21:30-43.
51. Araújo M.S., et al. Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis. Vaccine 2008, 26:2211-2224.
52. Poot J., et al. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants. Vaccine 2009, 27:4439-4446.
53. Lemesre J.L., et al. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 2005, 23:2825-2840.
54. Lemesre J.L., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 2007, 25:4223-4234.
55. Lasri S., et al. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes. Vet. Res. 1999, 30:441-449.
56. Holzmuller P., et al. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. Vet. Immunol. Immunopathol. 2005, 106:247-257.
57. Araújo M.S., et al. T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune. Vaccine 2009, 27:1008-1017.
58. Giunchetti R.C., et al. A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. Vaccine 2008, 26:623-638.
59. Giunchetti R.C., et al. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis. Res. Vet. Sci. 2008, 85:106-112.
60. Mayrink W., et al. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mem. Inst. Oswaldo Cruz 1996, 91:695-697.
61. Molano I., et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet. Immunol. Immunopathol. 2003, 92:1-13.
62. Ramiro M.J., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 2003, 21:2474-2484.
63. Rafati S., et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005, 23:3716-3725.
64. Poot J., et al. Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum. Vaccine 2006, 24:2460-2468.
65. Saldarriaga O.A., et al. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine 2005, 24:1928-1940.
66. Rodríguez-Cortés A., et al. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 2007, 25:7962-7971.
67. Fernandes A.P., et al. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008, 26:5888-5895.
68. Ramos I., et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 2008, 26:333-344.
69. da Silva V.O., et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN). Vaccine 2000, 19:1082-1092.
70. Borja-Cabrera G.P., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 2002, 20:3277-3284.
71. Borja-Cabrera G.P., et al. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine 2008, 26:4991-4997.
72. Freidag B.L., et al. Immunological and pathological evaluation of rhesus macaques infected with Leishmania major. Exp. Parasitol. 2003, 103:160-168.
73. Nylén S., et al. Surrogate markers of immunity to Leishmania major inleishmanin skin test negative individuals from an endemic area re-visited. Vaccine 2006, 24:6944-6954.
74. Day M.J. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Vet. Parasitol. 2007, 147:2-8.
75. Andrade A.M. A descriptive profile of the canine population in Araçatuba, São Paulo State, Brazil, from 1994 to 2004]. Cad. Saude Publica 2008, 24:927-932.
76. Nogueira F.S., et al. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 2005, 23:4805-4810.
77. Strauss-Ayali D., et al. Splenic immune responses during canine visceral leishmaniasis. Vet. Res. 2007, 38:547-564.